AG 120

Drug Profile

AG 120

Alternative Names: AG-120

Latest Information Update: 10 Feb 2017

Price : $50

At a glance

  • Originator Agios Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cholangiocarcinoma
  • Phase I/II Acute myeloid leukaemia
  • Phase I Glioma; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 09 Jan 2017 AG 120 receives Fast Track designation for Cholangiocarcinoma [PO] in USA
  • 09 Jan 2017 Agios Pharmaceuticals plans a phase III trial for Acute myeloid leukaemia (Combination therapy)
  • 31 Dec 2016 Phase-III clinical trials in Cholangiocarcinoma (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (PO) in December 2016 , (NCT02989857)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top